I don’t think they have to ‘re do’ the dosing, my understanding is dose selection is part of the early trial stage, to which they need a green light to move forward. I don’t know much about clinical trials but perhaps a way to derisk the whole study so they don’t go down the wrong path? Maybe one of the medical eggheads can confirm
Where we at?, page-272
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 445 | 1 |
View Market Depth
| Last trade - 09.41am 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable